CPRX

Catalyst PharmaceuticalsNasdaqCM:CPRX Stock Report

Market Cap

US$520.0m

7D

0.8%

1Y

50.3%

Updated

18 Sep, 2021

Data

Company Financials +
CPRX fundamental analysis
Snowflake Score
Valuation6/6
Future Growth2/6
Past Performance6/6
Financial Health6/6
Dividends0/6

CPRX Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Catalyst Pharmaceuticals
Historical stock prices
Current Share PriceUS$5.05
52 Week HighUS$2.88
52 Week LowUS$6.24
Beta1.34
1 Month Change-7.51%
3 Month Change-11.87%
1 Year Change50.30%
3 Year Change60.32%
5 Year Change304.00%
Change since IPO-17.21%

Recent News & Updates

Shareholder Returns

CPRXUS BiotechsUS Market
7D0.8%0.5%-0.6%
1Y50.3%25.9%33.8%

Return vs Industry: CPRX exceeded the US Biotechs industry which returned 25.7% over the past year.

Return vs Market: CPRX exceeded the US Market which returned 33.8% over the past year.

Price Volatility

Is CPRX's price volatile compared to industry and market?
CPRX volatility
CPRX Beta1.34
Industry Beta1.03
Market Beta1

Stable Share Price: CPRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: CPRX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200274Pat McEnanyhttps://www.catalystpharma.com

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3.

Valuation

Is Catalyst Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CPRX ($5.05) is trading below our estimate of fair value ($17.47)

Significantly Below Fair Value: CPRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CPRX is good value based on its PE Ratio (7x) compared to the US Biotechs industry average (25x).

PE vs Market: CPRX is good value based on its PE Ratio (7x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: CPRX is good value based on its PEG Ratio (0.8x)


Price to Book Ratio

PB vs Industry: CPRX is good value based on its PB Ratio (2.8x) compared to the US Biotechs industry average (3.2x).


Future Growth

How is Catalyst Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

8.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CPRX's forecast earnings growth (8.4% per year) is above the savings rate (2%).

Earnings vs Market: CPRX's earnings (8.4% per year) are forecast to grow slower than the US market (14.9% per year).

High Growth Earnings: CPRX's earnings are forecast to grow, but not significantly.

Revenue vs Market: CPRX's revenue (9.8% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: CPRX's revenue (9.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CPRX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Catalyst Pharmaceuticals performed over the past 5 years?

65.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CPRX has high quality earnings.

Growing Profit Margin: CPRX's current net profit margins (58.8%) are higher than last year (34.9%).


Past Earnings Growth Analysis

Earnings Trend: CPRX has become profitable over the past 5 years, growing earnings by 65% per year.

Accelerating Growth: CPRX's earnings growth over the past year (78.7%) exceeds its 5-year average (65% per year).

Earnings vs Industry: CPRX earnings growth over the past year (78.7%) exceeded the Biotechs industry 4.9%.


Return on Equity

High ROE: CPRX's Return on Equity (39.5%) is considered high.


Financial Health

How is Catalyst Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CPRX's short term assets ($176.3M) exceed its short term liabilities ($16.1M).

Long Term Liabilities: CPRX's short term assets ($176.3M) exceed its long term liabilities ($4.1M).


Debt to Equity History and Analysis

Debt Level: CPRX is debt free.

Reducing Debt: CPRX has not had any debt for past 5 years.

Debt Coverage: CPRX has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CPRX has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Catalyst Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CPRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CPRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CPRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CPRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CPRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Pat McEnany (74 yo)

19.67yrs

Tenure

US$1,762,272

Compensation

Mr. Patrick J. McEnany, also known as Pat, co-founded Catalyst Pharmaceuticals, Inc. (formerly known as Catalyst Pharmaceutical Partners Inc.) in January 2002 and has been its Chairman and President since...


CEO Compensation Analysis

Compensation vs Market: Pat's total compensation ($USD1.76M) is about average for companies of similar size in the US market ($USD1.67M).

Compensation vs Earnings: Pat's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CPRX's management team is seasoned and experienced (5.6 years average tenure).


Board Members

Experienced Board: CPRX's board of directors are seasoned and experienced ( 10.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CPRX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Catalyst Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Catalyst Pharmaceuticals, Inc.
  • Ticker: CPRX
  • Exchange: NasdaqCM
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$520.041m
  • Shares outstanding: 102.98m
  • Website: https://www.catalystpharma.com

Number of Employees


Location

  • Catalyst Pharmaceuticals, Inc.
  • 355 Alhambra Circle
  • Suite 801
  • Coral Gables
  • Florida
  • 33134
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 22:08
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.